Venn Life Sciences Holdings plc is a clinical research organization (CRO), which is engaged in providing a suite of consulting and clinical trial services to pharmaceutical, biotechnology and medical device organizations. The Company has the innovation segment, which is focused on developing and commercializing skin technologies. It provides drug development services through its subsidiary, Kinesis Pharma B.V. The Company's drug development services include clinical development, pharmaceutical development, non-clinical/pre-clinical development, drug candidate selection and drug development project management. The Company offers international clinical research services, including protocol development; feasibility and site selection; investigator and site selection; project management; site management and monitoring; vendor management, and quality assurance. The Company has its presence in the United Kingdom, Ireland, France, Netherlands, Germany and Singapore.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: LON:VENN
- CUSIP: N/A
- Web: www.vennlifesciences.com/
- Market Cap: £8.21 million
- Outstanding Shares: 60,284,000
- 50 Day Moving Avg: GBX 14.12
- 200 Day Moving Avg: GBX 16.27
- 52 Week Range: GBX 13 - GBX 29.39
Sales & Book Value:
- Trailing P/E Ratio: 13.625
- P/E Growth: 0.000
- Annual Revenue: £21.06 million
- Price / Sales: 0.39
- Book Value: GBX 0.20 per share
- Price / Book: 0.67
- EBIDTA: $270,503.00
- Net Margins: -7.67%
- Return on Equity: -20.08%
- Return on Assets: -9.22%
- Average Volume: 43,284 shs.
Frequently Asked Questions for Venn Life Sciences Holdings PLC (LON:VENN)
What is Venn Life Sciences Holdings PLC's stock symbol?
Venn Life Sciences Holdings PLC trades on the London Stock Exchange (LON) under the ticker symbol "VENN."
Who are some of Venn Life Sciences Holdings PLC's key competitors?
Some companies that are related to Venn Life Sciences Holdings PLC include Novogen Limited (NVGN), RXi Pharmaceuticals Corporation (RXII), OpGen (OPGN), Repros Therapeutics (RPRX), Roka Bioscience (ROKA), Ixico Plc (IXI), OncoGenex Pharmaceuticals (ACHV), Metabolix (YTEN), Synairgen plc (SNG), Jaguar Animal Health (JAGX), Akers Biosciences (AKR), Ampliphi Biosciences Corp (APHB), Rosetta Genomics (ROSG), Transgenomic (PRPO), Anacor Pharmaceuticals (ANAC), ANI Pharmaceuticals (BPAX), Celator Pharmaceuticals (CPXX) and Cellular Dynamics International (ICEL).
Who are Venn Life Sciences Holdings PLC's key executives?
Venn Life Sciences Holdings PLC's management team includes the folowing people:
- Allan Leigh Wood, Chairman of the Board
- Anthony Francis Richardson, Chief Executive Officer, Executive Director
- Jonathan David Hartshorn, Chief Financial Officer, Director
- Gracielle Anna Maria Beijerbacht-Schutjens, Executive Director
- Kees Groen, Executive Director
- Paul Francis Kennedy, Non-Executive Director
- Michael Ryan, Non-Executive Director
- Mary Blake Sheahan, Non-Executive Director
How do I buy Venn Life Sciences Holdings PLC stock?
Shares of Venn Life Sciences Holdings PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Venn Life Sciences Holdings PLC's stock price today?
MarketBeat Community Rating for Venn Life Sciences Holdings PLC (LON VENN)MarketBeat's community ratings are surveys of what our community members think about Venn Life Sciences Holdings PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Venn Life Sciences Holdings PLC stock can currently be purchased for approximately GBX 13.63.
Consensus Ratings for Venn Life Sciences Holdings PLC (LON:VENN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating|
|Consensus Rating:||Hold (Score: 2.00)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Venn Life Sciences Holdings PLC (LON:VENN)
(Data available from 8/19/2015 forward)
|10/5/2016||Beaufort Securities||Reiterated Rating||Speculative Buy|
Earnings History for Venn Life Sciences Holdings PLC (LON:VENN)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Venn Life Sciences Holdings PLC (LON:VENN)
Current Year EPS Consensus Estimate: $0.030 EPS
Dividend History for Venn Life Sciences Holdings PLC (LON:VENN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Venn Life Sciences Holdings PLC (LON:VENN)Insider Trades by Quarter for Venn Life Sciences Holdings PLC (LON:VENN)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/31/2016||Allan Wood||Insider||Buy||165,000||GBX 22||£36,300|
Headline Trends for Venn Life Sciences Holdings PLC (LON:VENN)
Latest Headlines for Venn Life Sciences Holdings PLC (LON:VENN)
Venn Life Sciences Holdings PLC (VENN) Chart for Saturday, August, 19, 2017